EGFR and glioblastoma: Our immunohistochemistry analysis of our own in-house SHH-GBM cohort (n = 60) revealed enhanced USP6NL expression, as represented by high Q-scores in the EGFR-amplified samples compared with their nonamplified or nontumor counterparts (nontumor << EGFRamp− << EGFRamp+) (Figure 1D).